BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:07 PM
Jun 25, 2007
 |  BC Extra  |  Clinical News

Viread meets endpoint in second HBV Phase III

Gilead (GILD) said 66.5% of Viread tenofovir patients had a complete response after 48 weeks, the primary endpoint, compared with 12.2% of patients receiving Hepsera adefovir dipivoxil in the Phase III Study 103 to treat...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >